Standard & Controlled-Release Levodopa/Carbidopa in Fluctuating Parkinson's Disease on a Protein Redistribution Diet
Arch Neurol 48:402-405, Karstaedt,P.J.,et al, 1991
Acquired Factor VIII Deficiency and Polyradiculoneuropathy
NEJM 324:1139, Garland,L.,et al, 1991
Does Ageing Aggravate Parkinsonisn Disability?
JNNP 54:780-782, Blin,J.,et al, 1991
Effect of Intramuscular Vitamin E on Mortality and Intracranial Hemorrhage in Neonates of 1000 Grams or Less
Pediatrics 85:578-584, Fish,W.H.,et al, 1990
Vitamin E for Prevention of Perinatal Intracranial Hemorrhage
Pediatrics 85:865-867, Poland,R.L., 1990
OKT3 Encephalopathy
Ann Neurol 28:837-838, Coleman,A.E.&Norman,D.J., 1990
"Stelazine"versus"Selegiline"-A Hazard in Prescription Writing, Letter
NEJM 323:1776, Kurth,M.C.,et al, 1990
Chronic Acetazolamide Monotherapy in the Treatment of Juvenile Myoclonic Epilepsy
Neurol 40:1677-1681, Resor,S.R.&Resor,L.D., 1990
Stereotaxic Thalamotomy-Experiences from the Levodopa Era
JNNP 53:427-430, Wester,K.&Hauglie-Hanssen,E., 1990
Sustained Enteral Administration of Levodopa Increases and Interrupted Infusion Decreases Levodopa Dose Requirements
Neurol 40:995-997, Cedarbaum,J.M.,et al, 1990
Pyramid Sale in the Bucket Shop:DATATOP Bottoms Out
Neurol 40:1337-1339, Landau,W.M., 1990
A Comparison of Effects of Controlled-Release Levodopa (Madopar CR) with Levodopa in Late Parkinson's Disease
JNNP 53:220-223, MacMahon,D.G.,et al, 1990
Tetrahydroaminoacridine-Lecithin Combination Treatment in Patients with Intermediate-Stage Alzheimer's Disease
NEJM 322:1272-1276, Gauthier,S.,et al, 1990
Neurotoxicity After Treatment with Muromonab-CD3
NEJM 323:487-488, Richards,J.M.,et al, 1990
Respiratory Dysfunction Due to L-Dopa Therapy for Parkinsonism:Diagnosis Using Serial Pulmonary Function Tests
Am J Med 89:109-114, Zupnick,H.M.,et al, 1990
Autoantibodies to Gaba-Ergic Neurons & Pancreatic Beta Cells in Stiff-Man Syndrome
NEJM 322:1555-1560, Solimena,M.,et al, 1990
Myopathy and Rhabdomyolysis Associated with Lovastatin-Gemfibrozil Combination Therapy
JAMA 264:71-75, Pierce,L.R.,et al, 1990
Cognitive Change Following MPTP Exposure
Neurol 40:261-264, Stern,Y.,et al, 1990
The Dystonias
BMJ 300:139-144, Marsden,C.D.&Quinn,N.P., 1990
Tacrine (tetrahydroaminoacridine; THA) and Lecithin in Senile Dememtia of the Alzheimer Type:A Multicentre Trial
BMJ 300:495-499, Chatellier,G.,et al, 1990
Mortality Associated with Early and Late Levodopa Therapy Initiation in Parkinson's Disease
Neurol 40:265-269, Scigliano,G.,et al, 1990
Dopa-Responsive Dystonia:The Spectrum of Clinical Manifestations in a Large North American Family
Neurol 40:66-69, Nygaard,T.G.,et al, 1990
Levodopa-Induced Dyskinesia:Review, Observations, and Speculations
Neurol 40:340-345, Nutt,J.G., 1990
Selegiline Use to Prevent Progression of Parkinson's Disease
Arch Neurol 46:1275-1279, Elizan,T.S.,et al, 1989
Effect of Deprenyl on the Progression of Disability in Early Parkinson's Disease
The Parkinson Study Group, NEJM 321:1364-13711989., , 1989
DATATOP:A Multicenter Controlled Clinical Trial in Early Parkinson's Disease
Parkinson Study Group, Arch Neurol 46:1052-10601989., , 1989
The Rational Management of Idiopathic Intracranial Hypertension
Arch Neurol 46:1049-1051, Corbett,J.J.&Thompson,H.S., 1989
Chronic Manganese Intoxication
Arch Neurol 46:1104-1106, Huang,C.C.,et al, 1989
Swallowing Abnormalities and Their Response to Treatment in Parkinson's Disease
Neurol 39:1309-1314, Bushman,M.,et al, 1989
Tetrahydroaminoacridine (THA) in Alzheimer's Disease, Not Ready for Routine Use
BMJ 298:845-846, Graham,T.R.&Lewis,C.T., 1989
Neoplastic Meningitis in Malignant Melanoma:Diagnosis with Monoclonal Antibodies
JNNP 52:881-886, Moseley,R.P.,et al, 1989
Pergolide and Selegiline for Parkinson's Disease
The Medical Letter, 31:81-841989., , 1989
Continuous Levodopa Infusions to Treat Complex Dystonia in Parkinson's Disease
Neurol 39:888-891, Sage,J.I.,et al, 1989
Dopa Responsive Dystonia:A Treatable Condition Misdiagnosed as Cerebral Palsy
BMJ 298:1019-1020, Boyd,K.&Patterson,V., 1989
Long-Term Efficacy and Safety of Deprenyl (Selegiline) in Advanced Parkinson's Disease
Neurol 39:1109-1111, Golbe,L.I.,et al, 1989
The Effect of Deprenyl (Selegiline) on the Natural History of Parkinson's Disease
Science 245:519-522, Tetrud,J.W.&Langston,W., 1989
Amount and Distribution of Dietary Protein Affects Clinical Response to Levodopa in Parkinson's Disease
Neurol 39:552-556, Carter,J.H., 1989
The Effect of Dietary Protein on the Efficacy of L-Dopa:A Double-Blind Study
Neurol 39:549-552, Tsui,J.K.,et al, 1989
Diffuse Lewy Body Disease:Clinical Features in 15 Cases
JNNP 52:709-717, Byrne,E.J., 1989
Lisuride, A Dopamine Agonist in the Treatment of Early Parkinson's Disease
Neurol 39:336-339, Rinne,U.K., 1989
A Double-Blind Crossover Comparison of Sinemet CR4 and Standard Sinemet 25/100 in Patients with Parkinson's Disease
JNNP 52:207-212, Cedarbaum,J.M.,et al, 1989
Efficacy of Sinemet CR4 in Subgroups of Patients with Parkinson's Disease
JNNP 52:83-88, Factor,S.A.,et al, 1989
Dose-Dependent Memory Impairment in Parkinson's Disease
Neurol 39:438-440, Huber,S.J.,et al, 1989
Controlled Release of Dopamine from a Polymeric Brain Implant:In Vivo Characterization
Ann Neurol 25:351-356, During,M.J.,et al, 1989
Current Theories on the Cause of Parkinson's Disease
JNNP Suppl (June) 52:13-17989., Langston,J.W., 1989
Paroxysmal Cerebellar Ataxia
Aust NZ J Med 19:113-117, Feeney,G.F.&Boyle,R.S., 1989
Diabetic Neuropathy, Structural Analysis of Nerve Hydration by Magnetic Resonance Spectroscopy
JAMA 260:2872-2878, Griffey,R.H.,et al, 1988
Serum Antibodies to GM1 Ganglioside in Amytrophic Lateral Sclerosis
Neurol 38:1457-1461, Pestronk,A.,et al, 1988
Tardive Dyskinesia
BMJ 296:150-151, Barnes,T.R.E., 1988
Immunotherapy of Multiple Sclerosis
Ann Neurol 23:211-223, Weiner,H.L.&Hafler,D.A., 1988